Xilis operates as a biotechnology company for the treatment of cancer patients. It provides MicroOrganoSphere (MOS) platform that enables personalized rapid diagnostics for immuno-oncology. Its technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. The company was founded in 2019 and is based in Durham, North Carolina.
ESPs containing Xilis
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The organ-on-a-chip market focuses on creating micro-scale models of human organs using microfluidic technology. This market offers a range of solutions that simulate complex biological processes that occur within organs, including drug metabolism, toxicity testing, and disease modeling. By using organ-on-a-chip models, researchers can reduce the need for animal testing, accelerate drug developmen…
Research containing Xilis
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Xilis in 3 CB Insights research briefs, most recently on Aug 10, 2023.
Expert Collections containing Xilis
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Xilis is included in 4 Expert Collections, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Early-Stage Pharma Market Map
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Xilis has filed 4 patents.
Biotechnology, Molecular biology, Transcription factors, Cell biology, Oncology
Biotechnology, Molecular biology, Transcription factors, Cell biology, Oncology
Latest Xilis News
May 15, 2023
Pear Bio uses microtumours taken from patient cells to predict how cancer will respond to treatments 3 min read Pear Bio, a techbio startup working to improve the efficacy of cancer drug treatments, has raised a $14m Series A round led by Octopus Ventures. It’s one of many techbio startups in Europe that have raised cash to improve the fix drug and treatment discovery — especially in cancer. Almost 30% of the $5.2bn that went to techbio startups in Europe in 2022 went to companies focused on oncology. Pear Bio takes samples from tumour cells and breaks them into micro-tumours of 10k cells each, which are then used to test the effectiveness of different drugs like cancer treatments, immunotherapy and anticoagulants. Results from these tests are combined with clinical data to power predictive models, which suggest how a specific patient will respond; the company uses computer vision software to visualise how the tumours are affected. Advertisement The special sauce, founder Duleek Ranatunga tells Sifted, lies in the fact that the company tests micro-tumours but also the immune cells in the blood surrounding them. Considering these extra cells in the testing process means that Pear Bio can show how treatments affect both the tumour and a patient’s immune response. So far, the startup has partnered with pharmaceutical companies to test new drugs on cells from 220 patients in R&D and clinical studies. These tests compared the treatment outcome predicted by Pear Bio’s model to the actual reaction, to demonstrate the platform’s accuracy. The tumour cells left over after treatments are fed into the startup’s drug discovery efforts, so it can study them and find out why they didn't respond to treatment. Those discoveries can then be used to develop new treatments. The company is currently focused on certain kinds of rare breast cancer and kidney cancer. Why do we need it? Cancer treatments are complex, especially when they’re combined, like using a drug and immunotherapy together. That makes it difficult to accurately mirror real-world conditions for testing the efficacy of treatment plans. Pear Bio’s patient-tailored approach can work with the complexity of more complicated cancer cells, and hopes to improve the recovery rates of cancers that are currently underserved by the sector. This approach means that samples are both smaller and more complex, but combining them with computational models and wider clinical data can mitigate this. Sifted Newsletters Join to Sign Up While the long time to market of novel drugs means that current patients won’t be able to benefit from new treatments developed from the targets in their tumour cells, the use of public databases to work out how frequently the mutations and proteins emerge in the general population of cancer patients can help future cases. How’s the sector looking? Pear Bio has lots of competitors in the precision medicine space — Xilis, a US-based precision platform technology developer, has a similar process with breaking down tumours to test treatments. According to Ranatunga, however, Pear Bio’s process is faster, returning test results in less than a week compared to the 10 days that Xilis needs. Once at clinical application stage, he highlights, this time saved could be vital for a cancer patient’s chance of successfully responding to treatment. Want investment-grade insight into the oncology sector? Read out Cancer therapeutics Briefing to meet the rising stars and success stories in Europe's startup scene. Available to Sifted subscribers. Advertisement
Xilis Frequently Asked Questions (FAQ)
When was Xilis founded?
Xilis was founded in 2019.
Where is Xilis's headquarters?
Xilis's headquarters is located at 31 Alexandria Way, Durham.
What is Xilis's latest funding round?
Xilis's latest funding round is Series A - II.
How much did Xilis raise?
Xilis raised a total of $94M.
Who are the investors of Xilis?
Investors of Xilis include Pear VC, Two Sigma Ventures, Google Ventures, Felicis, Catalio Capital Management and 11 more.
Who are Xilis's competitors?
Competitors of Xilis include Kiyatec.
Compare Xilis to Competitors
Ocimum Biosolutions is a life sciences RnD enabling company with three focus areas, BioIT (LIMS / Bioinformatics), BioMolecules, and BioResearch. Ocimum aims to deliver end to end genomic products and services out of three strategic locations worldwide, Indianapolis (United States), IJsselstien (The Netherlands), Hyderabad (India).
Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.
Virmatics is a bioinformatics software company developing efficient, and automated tools for biomedical researchers. Their software aims to give researchers the ability to plan experiments and record, store, and analyze data with unparalleled flexibility. Virmatics has been a member of the incubator since Fall 2004.
Rhenovia Pharma is a French biotechnology company founded in 2007 by an international team that brings together managers from large pharmaceutical companies and world experts in neuroscience and nervous system modeling. The company is a provider in the application of biosimulation in the prevention and treatment of neurological, neurodegenerative and psychiatric disorders and diseases.
Kiyatec specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision-making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to the current standard of care drugs prior to treatment selection. The company was founded in 2005 and is based in Greenville, South Carolina.
Velocity11 broadly covers the life science automation market, with a concentration in drug discovery, genomics, and proteomics applications. Through direct distribution, value added reseller channels, and a multi-continent customer service, applications, and support organization, Velocity11 strives to deliver an outstanding user experience to our customers globally. Velocity11 works to maintain an intimate relationship with each of our customers across over 3,500 installations, including all of the blue-chip pharmaceutical companies, top biotechnology companies, and leading academic institutions in the world. Through these customer relationships, coupled with our world-class technical teams, Velocity11 develops cutting edge solutions that meet the demanding needs of life science automation applications.